Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (July 2021)
22 slides from Infusystems's investor presentation, Jul 6, 2021
Slide 1: Investor Presentation June 2021
System SAFE. SMART. TRUSTED” Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation JUNE 2021 | (NYSE American: INFU)
Slide 2: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward-Looking Statement Certain statements contained In this presentation are forward-looking statements, ‘within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended,
Slide 3: Double-digit growth through two proven business platforms
Double-digit growth through two proven business platforms: Durable Medical Equipment (DME) and Integrated Therapy Services (ITS) ‘Market data as of $/10/21 TRUSTED. Providing best-in-class durable medical equipment and patient services facilitating clinic-to-home care $10B North American Home DME ma
Slide 4: Focus, Scale and Experience
Focus, Scale and Experience @ Aleading North American provider of equipmentand services with 100K+ device fleet @ 34-year history, perfected model in Oncology and now expandinginto multiple therapies Seven major service areas in the U.S. and Canada with over 300 employees National scale, serving 8 o
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $36.3M (37%) DURABLE MEDICAL EQUIPMENT (DME) SUPPORT SERVICES ITS $61.1M (63%) Total 2020 Equipment and consumable Revenue: sales/lease to hospitals, clinics INTEGRATED THERAPY SERVICES (ITS) $97.4 Mi
Slide 6: Well-Diversified & Strategic Payer Relationships
Well-Diversified & Strategic Payer Relationships Percentage of Cash Collected by Payer 2020 Medicaid: 1.3% Uninsured: 0.3% a el 6,500+ Direct Pay Hospital and Alternate Site Customers Hospital/Alternate Site Direct Pay: 47.7% Commercial Payer: 50.7% No Single Payer Greater Than 11.0% (InfuSystem
Slide 7: DME Platform
DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model es to Maintenance © Pump rentals and VAR sales (new devices) @ Broker/trader sales (used devices) @ Biomedical service and repair © Direct payer model: INFU is paid directly by the hospital/clinic/homecare provider (InfuSys
Slide 8: ITS Platform
ITS Platform Unique and Scalable, High-Margin, High-Service Model Clinical Si Device Repair & Maintenance © supply medical equipment and proprietary consumables for outpatient care @ Hospital, clinician and patient customer service @ Third-party payer model: INFUis paid by the patient’s medical insu
Slide 9: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based on Unique Focus, National Scale and Established Payer Network InfuSystem 24/7 Nursing Tea continuous patient supportto mi at select sites —see sites below. CHAP Accredited. canny i unercrfocarumberFUSSE23 0 34S lage DevceltaragearSyucerted b
Slide 10: Growth Strategy of ITS Platform
Growth Strategy of ITS Platform Adding New High-Margin Therapy Segments Oncology Pain Management Negative Pressure ‘Wound Therapy Future Therapies Go-to-Market Established Evaluation | Strategy Launch | Growth/Traction “@ Leverage recognized core competencies to gain and therapy leadership _-- $97.4
Slide 11: Highly Scalable Existing Infrastructure
Highly Scalable Existing Infrastructure Foundation BuiltIn Oncology: Leveragelt Multiple New Therapies Can Be Added With Times (Pain, NPWT, Future Therapies) Minimal Incremental Expense Oncology & Pain Management NPWT Offices and Logistics Future Therapies 34 Years of Experience, + Full North Americ
Slide 12: ITS Model: Platform Proven in Oncology
ITS Model: Platform Proven in Oncology InfuSystem ITS Value Proposition Opportunity: Oncology Home Treatment * Large capital expense for clinics in addition to maintenance and nightly triage * Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient Trea
Slide 13: First Quarter Financial Results
First Quarter Financial Results MM 52: Net Revenue 2021 ia 2020 ES 521.61 Net Income (Loss) 2021 I $0.7 2020 I ($0.4m) ‘a 2021 MEE se.2m AEBITDA Oe mss 2021 MM $2.7 idle 2020 Wf $o.6m (1) See Appendix A. es Alaiyston
Slide 14: Full Year Financial Results
Full Year Financial Results 2020 ns $97.4 Net Revenue 2019 es $31.1 2020 MEE $17.3m Net Income 2019 1 $1.4m 5 2020 MEE s26.4m AEBITDA” A 2019 ME sis.4m 2020 MEE s20.3m Op Cash P Flow 2019 ME s13.0m (1) See Appendix A. é Alaiyston
Slide 15: Financial Trend & Current 2021 Guidance
Financial Trend & Current 2021 Guidance Net Revenues") & AEBITDA) $107.0- $110.0 se 's)anusroy usr s)vaneaw (uo 20174 20188 20198 20208 20216 I rousitettoverse f= AamalAcaToA HN QLYIONetReveme ——[}- LYTOAGRTOA Notes: 12017 consolidated revenueshavebeen adjustedto reflec the effect ofthe adoption of
Slide 16: Financial Trend & Current Targets
Financial Trend & Current Targets Cash Flows From Operations $21.0 -$23.0 25% Guonws) ‘anuaAay ION JO % CinfuSystem
Slide 17: Recent Accomplishments & Corporate Priorities
Recent Accomplishments & Corporate Priorities ‘Acquisition and integration of two biomedical services companies; enabling entry into acute care service market — Early 2021 = ‘Strong execution despite extemal forces and conditions; particularly the pandemic — 2020 \djusted EBITDA and operating cash f
Slide 18: Richard Diorio
Richard Diorio het Executive Officer & Joined infusystem executive leam Seasoned Industry Experience, Including: Pharmaceutical, Health Care, Life Sciences, Medical Device, Automotive OEM, Public Accounting, Military, Retail, Consumer Brands, Digital Advertising, Consulting & High-Tech
Slide 19: Summary
Summary Two proven platforms that enable the delivery of patient care from the clinicinto the home, driving double-digit revenue, cash flow growth and accelerating profit Market opportunities driven by rising health care costs, an aging population, medical innovation, patient satisfaction and other
Slide 20: Questions & Answers
SAFE. SMART. TRUSTED” Questions & Answers
Slide 21: Appendix A: GAAP to Non-GAAP Reconciliation
Appendix A caap to NON-GAAP Reconciliation ‘Twelve Months Ended ‘Three Months Ended NET INCOME (LOSS) TO ADJUSTED EBITOA: Leeclncaiboes Sackth {in thousands) 2017 2018 2019 2020 2020 2021 GAAP net income (loss) (20,707) (2,095) 1,361 17,332 (418) 661 Adjustments: Interest expense 1,332 1,420 1,904 4
Slide 22: Appendix B: Select Balance Sheet Data
Ap pen IX B setect Balance sheet Data December31, December 31, March 31, 2019 2020 2021, {ia Thousands, xcept Share Data) Cash and Cash Equivalents $2,647 $ 9648 $2,761 Available Liquidity 21,258 19,685 44,961 one oe 2,893 6,549 9,239 Medical Equipment, Net 33,225 35,611 35,769 Total Assets 79,224 9
InfuSystem Holdings — Investor Presentation (July 2021) on 6ix